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Abstract
Background: Bacteroides thetaiotaomicron (Bt) is a prominent member of the human intestinal microbiota that, like
all gram-negative bacteria, naturally generates nanosized outer membrane vesicles (OMVs) which bud off from the
cell surface. Importantly, OMVs can cross the intestinal epithelial barrier to mediate microbe-host cell crosstalk
involving both epithelial and immune cells to help maintain intestinal homeostasis. Here, we have examined the
interaction between Bt OMVs and blood or colonic mucosa-derived dendritic cells (DC) from healthy individuals
and patients with Crohn’s disease (CD) or ulcerative colitis (UC).
Results: In healthy individuals, Bt OMVs stimulated significant (p < 0.05) IL-10 expression by colonic DC, whereas in
peripheral blood-derived DC they also stimulated significant (p < 0.001 and p < 0.01, respectively) expression of IL-6
and the activation marker CD80. Conversely, in UC Bt OMVs were unable to elicit IL-10 expression by colonic DC.
There were also reduced numbers of CD103+ DC in the colon of both UC and CD patients compared to controls,
supporting a loss of regulatory DC in both diseases. Furthermore, in CD and UC, Bt OMVs elicited a significantly
lower proportion of DC which expressed IL-10 (p < 0.01 and p < 0.001, respectively) in blood compared to controls.
These alterations in DC responses to Bt OMVs were seen in patients with inactive disease, and thus are indicative of
intrinsic defects in immune responses to this commensal in inflammatory bowel disease (IBD).
Conclusions: Overall, our findings suggest a key role for OMVs generated by the commensal gut bacterium Bt in
directing a balanced immune response to constituents of the microbiota locally and systemically during health
which is altered in IBD patients.
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Introduction
The human gastrointestinal (GI) tract contains an esti-
mated 3.8 × 1013 bacteria (1011/mL contents) that play
an essential role in digestion, pathogen resistance and
the development of different sensory systems within the
GI tract including the immune system [1–3]. Gram-
negative Bacteroides thetaiotaomicron (Bt) is a promin-
ent member of the intestinal microbiota of many ani-
mals [4–6]. Bt has important functions in nutrient
absorption and promoting barrier function via its effect
on goblet cell development and mucus secretion [7, 8].
In addition, Bt has been described to be both protective
and pathogenic in rodent models of intestinal inflamma-
tion [9–11]. Typical of all gram-negative bacteria, Bt
generates nanosized outer membrane vesicles (OMVs)
during its normal growth [12, 13]. The content of OMVs
is varied, including enzymes and hydrolases, cell-wall
components such as lipooligosaccharide and peptidogly-
can, nucleic acids and metabolites [14–16]. Importantly,
OMVs are packaged within a lipid bilayer which protects
them from physical, chemical and biological degradation
within the GI tract [17, 18].
The production of OMVs by pathogenic gram-
negative bacteria including Vibrio cholerae, Neisseria
meningitidis, Helicobacter pylori and Haemophilus influ-
enzae plays a central role in infection and the delivery of
toxins to host cells, and stimulation of the immune sys-
tem [13, 19–22]. OMVs produced by commensal bacter-
ial species of the genus Bacteroides have been implicated
in microbial and immune homeostasis. For example,
polysaccharide A expressed on the surface of OMVs
from Bacteroides fragilis can promote both regulatory T
cell responses and production of interleukin (IL)-10 by
dendritic cells (DC) in a TLR-2 and Gadd45α-dependent
manner that contributes to protection in a mouse model
of acute colitis [23]. Bt produces OMVs containing
phosphatases and sulfatases which are implicated in epi-
thelial intracellular signalling and immunomodulatory
functions [24, 25]. In fact, OMVs from both pathogenic
and commensal strains have been used in vaccine for-
mulations, supporting their role in microbe-host im-
mune system crosstalk [26–29].
Most of our understanding of OMVs-host interactions
comes from animal model systems with the human im-
mune response to Bt and OMVs being poorly charac-
terised. Therefore, we have examined how DC from
healthy individuals respond to Bt OMVs and how these
responses change in individuals with inflammatory
bowel disease (IBD). The IBDs, including Crohn’s dis-
ease (CD) and ulcerative colitis (UC), are chronic,
relapsing-remitting diseases of the GI tract affecting
more than 0.3% of western populations [30]. Both CD
and UC are characterised by destruction of the mucosal
barrier leading to inappropriate responses to the
microbiota. These altered responses stem from changes
in the underlying immune system, including loss of key
populations of regulatory innate and adaptive immune
cells leading to overexuberant pathogenic T cell re-
sponses [31–36]. These changes are also associated with
intestinal microbial dysbiosis characterised by reductions
in Bacteroidetes and Firmicutes with concomitant in-
crease in Proteobacteria [37].
IL-10 is an immunoregulatory cytokine and is essential
for intestinal homeostasis as demonstrated in mice lack-
ing either IL-10 or IL-10 receptor genes that spontan-
eously develop inflammatory disease [38, 39]. IL-10 is
important for regulating T cell responses to the com-
mensal microbiota and largely acts via the innate im-
mune system, including macrophages and DC [40–42].
In humans, the importance of the IL-10 pathway in
regulating immune response is clear from patients with
monogenic defects in IL10 and IL10R genes that develop
rapid onset IBD [43–45].
DC are key antigen-presenting cells that both produce
and respond to IL-10 to regulate immune responses [42,
46], with both human studies and mouse models dem-
onstrating their central role in immune homeostasis and
microbial tolerance [47–50]. This, together with the al-
terations to DC subsets in IBD [32–34, 51, 52], led us to
hypothesise that DC are key effectors in the healthy re-
sponse to Bt that is mediated by OMVs and that DC re-
sponses to Bt-derived OMVs may be altered in IBD.
Results
Bt OMVs elicit production of immunoregulatory IL-10 by
DCs of the healthy human colon
During normal anaerobic growth, Bt cells produce and
release OMVs into the external milieu which consists of
nanostructures exhibiting a typical spherical lipid bilayer
(Fig. 1a) [53]. In order to examine mucosal immune re-
sponses to OMVs, colonic biopsies from healthy individ-
uals (see Table 3) were cultured intact in a polarised
in vitro culture system (pIVOC) for 6 h with 108-109 Bt
OMVs/mlor medium alone added to the apical surface.
Immune mediators were then measured in tissue lysates.
Amongst the panel of 13 cytokines/chemokines tested
(see the “Methods” section) all but IFNα2 were induced
at detectable levels though TNF-α, IL-17a, IL-12p70 and
IL-23 were very low (< 5 pg/ml) (Supplementary Figure
1a). Those cytokines significantly upregulated in re-
sponse to OMVs were chemoattractant MCP-1 (CCL2)
(p < 0.001), IFN-γ (p < 0.01), IL-8, IL-1β, IL-6 and not-
ably IL-10 (all p < 0.05; Fig. 1b).
To determine if DC were a source of cytokines in the
pIVOC system, total lamina propria (LP) cells were ob-
tained from five distal and five proximal colonic biopsies by
enzymatic digestion and were cultured for 20 h in the pres-
ence of either non-viable (freeze-killed) Bt (107 cfu/mL), Bt
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OMVs (1010/mL) or medium only. DC was identified as
HLA-DR+ cells which did not express CD14 or CD64,
markers of macrophages or monocytes (Fig. 1c). The ma-
jority (> 60%) of DC expressed CD11c, a marker of myeloid
(m)DC and were activated by both Bt and its OMVs as
shown by increased expression of HLA-DR (Fig. 1d). Fur-
ther, while a proportion of LP mDC expressed IL-6 (5-10%)
in response to Bt and OMVs, a greater and significant (p <
0.05) proportion of mDC expressed IL-10 in response to ei-
ther Bt or Bt OMVs (10-30%) compared to medium-only
control cultures (Fig. 1e), consistent with DC being a source
of IL-10 detected in intact colonic biopsies (Fig. 1b). Im-
portantly, absolute numbers of mDC expressing IL-10, but
not IL-6, were also significantly increased (p < 0.05) after
culture with Bt or Bt OMVs compared to the medium-only
condition (Supplementary Figure 1b). Thus, in health, IL-
10 is a predominant cytokine produced locally by DC in
the colon in response to Bt and Bt OMVs.
Bt and Bt OMVs promote protective circulating DC
responses
To determine whether Bt and Bt OMVs elicited a similar
response from circulating DC, peripheral blood mono-
nuclear cells (PBMC) from healthy donors were stimu-
lated with Bt or varying doses of Bt OMVs for 20 h and
DC responses were examined by multiparameter flow
cytometry. DC were identified within PBMC based upon
the absence of expression of lineage-specific markers
(CD3/CD14/CD16/CD19/CD34) and being HLA-DR+.
Within this population, both CD11c+ mDC and CD123+
plasmacytoid (p)DC were identified with mDC predom-
inating (Fig. 2a).
To examine how DC responded to culture with Bt and
Bt OMVs, expression of the activation marker CD80 and
intracellular cytokines IL-6 and IL-10 were measured by
flow cytometry. Results are displayed as percentages of
total mDC and pDC staining positively for these
Fig. 1 Bt OMVs stimulate production of immunoregulatory IL-10 from whole colonic biopsies and colonic LP DC. During normal anaerobic
growth, Bt cells produce and release OMVs into the external milieu. a Electron microscope photograph of OMVs collected by sterile filtration of Bt
culture supernatants through 0.22 μm membranes. Red arrows point to spherical nanostructures consisting of lipid bilayer. Scale bar, ~ 100 nm.
Colonic biopsies taken from the rectosigmoid junction of healthy individuals were grown in a pIVOC system mucosal side up within Snapwell
inserts for 6 h in IVOC medium with or without 108-109 Bt OMVs. b Following culture, biopsies were snap-frozen and cytokines and chemokines
were measured within tissue lysates by LEGENDplex cytokine bead array. Amounts of MCP-1, IFN-γ, IL-8, IL-1β, IL-6, and IL-10 shown are mean ±
SEM values from n = 4 healthy controls with two experimental replicates each. Statistical significance was determined using nonparametric
Mann-Whitney U tests; *p < 0.05; **p < 0.01; ***p < 0.001. Five biopsies each from proximal and distal colon of healthy individuals were washed
with DTT/EDTA and digested with collagenase/liberase to obtain total LP cells. Cells were then cultured for 20 h in the presence of either killed
107 Bt/mL or 1010 Bt OMV/mL in complete RPMI medium, and mDC were examined by flow cytometry. c Identification of mDC within the total
LP cells. d Mean fluorescence intensity of HLA-DR on total mDC in response to medium only, Bt or Bt OMVs. Statistical significance was
determined by one-way ANOVA with Dunnett’s multiple comparisons test; *p < 0.05. e Proportion of mDC expressing IL-6 (top panel) and IL-10
(bottom panel) within the colonic LP. Pooled data from n = 6 HC. Statistical significance was determined using non-parametric Kruskal-Wallis
ANOVA with Dunn’s multiple comparisons test; *p < 0.05
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markers. Both Bt and Bt OMVs activated mDC and pDC
as seen by expression of co-stimulatory marker CD80 on
the majority of mDC (60-80%) and a major proportion
of pDC (40-50%) (Fig. 2b). However, cytokine responses
were predominated by mDC with 30-60 % expressing
IL-6 in response to Bt and to a range of concentrations
of Bt OMVs (Fig. 2c) while only small proportion of
pDC (< 10%) produced IL-6 in response to high concen-
trations of Bt OMVs (Supplementary Figure 2a and b).
Importantly, IL-10 was expressed by a significant (p <
0.01) proportion of mDC (10-15%) in response to both
Bt and a range of Bt OMV concentrations but not by
pDC (Fig. 2c and Supplementary Figure 2a and b). When
levels of cytokines were measured in culture superna-
tants, there was compared to control cultures a signifi-
cant (p < 0.01) amount of IL-6 in response to the
highest concentration of Bt OMVs (109/mL), while IL-
10 was detected in response to Bt OMVs at
concentrations of ≥ 108/mL (p < 0.05) (Fig. 2d). These
findings suggest that, as seen with mucosal DC, circulat-
ing immune responses to Bt OMVs in healthy individ-
uals involve a balance of protective IL-6 and regulatory
IL-10.
Reduced IL-10 response to Bt OMVs and associated loss
of CD103+ DC in IBD
CD and UC are characterised by a loss of mucosal bar-
rier integrity, leading to translocation of bacteria and
triggering of inappropriate immune responses. Alter-
ations in colonic DC populations, including loss of regu-
latory CD103+ DC, have been demonstrated in IBD [33,
34, 49, 50]. We confirmed these findings in our patient
cohort (see Table 1) by characterising mDC in LP cells
from proximal and distal colon of healthy controls (HC)
and individuals with CD and UC, including expression
of CD103 and SIRPα (a myeloid marker) which
Fig. 2 Bt OMVs activate and stimulate both IL-6 and IL-10 expression from healthy circulating DC. PBMC were prepared from healthy individuals.
a Following 20 h culture in the presence of Bt or varying concentrations of Bt OMVs, DC were identified within live cells as HLA-DR+ Lineage
(CD3/14/16/19/34)− cells and further subdivided into CD11c+ myeloid DC or CD123+ pDC. b Pooled data (n = 4) showing proportion of mDC
(top panel) and pDC (bottom panel) expressing activation marker CD80. Statistical significance was determined by ordinary one-way ANOVA with
Dunnett’s multiple comparisons test; *p < 0.05; **p < 0.01. c Intracellular cytokine expression by mDC in response to Bt and OMVs is shown as a
proportion of mDC expressing IL-6 (top panel) or IL-10 (bottom panel). Statistical significance was determined by one-way ANOVA with Brown-
Forsyth and Welch corrections for unequal variance and with Dunnett’s T3 multiple comparisons tests; *p < 0.05; **p < 0.01; ***p < 0.001. d Total
amounts of secreted IL-6 (top panel) and IL-10 (bottom panel) were measured by ELISA in culture supernatants taken at 20 h. Data shown is
pooled from n = 3-4 HC. Statistical significance was determined by ordinary one-way ANOVA with Dunnett’s multiple comparisons test (IL-10) or
non-parametric Kruskal-Wallis ANOVA with Dunn’s multiple comparisons test (IL-6); *p < 0.05, **p < 0.01
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subdivides mDC into SIRPα+ CD103− (similar to
monocyte-derived DC), SIRPα+ CD103+ (similar to CD1c+
cDC2) and SIRPα−CD103+ (similar to CD141+cDC1) DC
[54–56]. Individuals with UC and CD were subdivided
into active (red symbols) or inactive (black symbols) dis-
ease based on histological findings (Table 1) and blood or
faecal markers of inflammation (Table 2). Inactive disease
was defined as having macroscopically normal mucosa
from rectum to terminal ileum (TI) from colonoscopy
and/or not having inflammatory markers in blood and fae-
ces at time of sampling. Absolute numbers of mDC were
unchanged in IBD compared to HC, regardless of disease
activity (Supplementary Figure 3a). Total CD103+ mDC
were also only significantly reduced (p < 0.05) in the prox-
imal colon of CD patients (Supplementary Figure 3b) and
specifically those with active disease trended towards sig-
nificance (p = 0.0562) Further, when CD103+ mDC were
subdivided based on expression of SIRPα, both SIRPα+
CD103+ and SIRPα−CD103+ DC were significantly re-
duced (p < 0.05; p < 0.05) in the proximal colon of all CD
patients, along with SIRPα−CD103+DC being substantially
reduced (p = 0.0512) in the distal colon of all UC patients
compared to HC (Supplementary Figure 3c, top and mid-
dle panels). However, when UC and CD patients were
subdivided based on disease activity, only CD patients
with active disease had substantial reductions (p = 0.0885)
in SIRPα+ CD103+ DC and significant reductions (p <
0.05) in SIRPα−CD103+ DC. The numbers of SIRPα+
CD103− DC in either the proximal or distal colon of UC
and CD patients were not different to HC (Supplementary
Figure 3c; bottom panels) and this held true when patients
were subdivided based on disease activity. Thus, both CD
and UC are characterised by loss of CD103+ DC in the co-
lonic LP and in CD the loss of CD103+ DC occurred in in-
dividuals with active disease.
Having confirmed alterations in DC populations in
IBD patients, we next investigated if the immune re-
sponse to Bt OMVs was also altered in IBD patients.
To this end, total LP cells from distal and proximal
colon of UC patients (all with mild active (Mayo 1)
disease as defined by histological findings (Table 1),
and blood/faecal inflammatory markers (Table 2) were
stimulated for 20 h with 1010 Bt OMV/mL or medium
only and intracellular cytokine expression by DC was
examined. Unlike in HC, Bt OMVs did not stimulate
a significant proportion of mDC from LP of UC pa-
tients to express IL-6 or IL-10 (Fig. 3a). Likewise,
despite similar numbers of total mDC in UC and HC,
absolute numbers of IL-6- or IL-10-expressing mDC
were not increased by Bt OMVs in UC (Supplemen-
tary Figure 4a and b). There was a non-significant
trend towards reduced proportions and absolute num-
bers of mDC expressing both IL-6 and IL-10 in UC
compared to HC (Fig. 3b and Supplementary Figure
4c). Thus, these findings suggest a loss of immuno-
regulatory DC response to Bt OMVs in UC which
Table 1 Clinical characteristics of St Mark’s Hospital colonoscopy patients donating colonic biopsies
Characteristic Healthy control (HC) Ulcerative colitis (UC) Crohn’s disease (CD)
n 27 14 10
Male/female 11/16 7/7 3/7
Age at sampling 51 (20-77) 47.3 (24-70) 47.2 (21-77)
Inflammation categories
None 4 4
Mayo 1 (mild disease) 5 3
Mayo 2 (moderate disease) 5 1
Mayo 3 (severe disease) 0 1
Perianal disease 0 0
Chronic obstruction 0 0
Terminal ileum resection 0 1
IBD medications at sampling
None 8 5
Aminosalicylates 5 3
Azathioprine/6-mercaptopurine 1 3
Buscopan 0 1
Non-IBD medications at sampling
Ondansetron 0 1
None 14 9
Demographic and clinical data analysed in Figs. 1, 2, 3, 4 and 5 and Supplementary Figs 1-4
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may in part be explained by the reduction in immu-
noregulatory CD103+ DC in these patients (Supple-
mentary Figure 3).
Circulating DC IL-10 response to Bt OMVs is also reduced
in both UC and CD
To assess whether changes in colonic DC and response to
Bt OMVs in IBD were reflected systemically in individuals
with CD or UC, PBMC were used to examine circulating
DC responses. In these experiments, disease activity was
determined for UC and CD patients using both macro-
scopic histological findings from colonoscopy (Table 1)
and blood or faecal markers of inflammation (Table 2). In-
active disease was defined as having macroscopically nor-
mal mucosa from rectum to terminal ileum (TI) from
colonoscopy and/or not having inflammatory markers in
blood and faeces at time of sampling.
As in Fig. 2a, mDC were identified in PBMC as
CD11c+HLA-DR+ lineage marker (CD3/14/16/19/34)
negative cells. To examine how mDC responded to cul-
ture with Bt and Bt OMVs, expression of intracellular cy-
tokines IL-6 and IL-10 were measured by flow cytometry.
Results are displayed as percentages of total mDC staining
positively for these markers. Following 20 h culture, a sig-
nificant proportion of mDC expressed IL-6 in response to
both Bt and high doses of Bt OMVs in both inactive UC
(≥ 109 OMVs/mL) or inactive CD (≥ 109 OMVs/mL) pa-
tients, which was comparable to the response of mDC
from HC (Fig. 4a). However, neither Bt nor OMVs in-
duced significant expression of IL-10 by mDC in inactive
UC patients and the proportion of mDC that expressed
IL-10 was significantly lower (p < 0.001; p < 0.05) than
that of HC at high doses of OMVs (≥ 109 OMVs/mL)
(Fig. 4b). In patients with inactive CD, a low but signifi-
cant (p < 0.05) proportion of mDC (10%) expressed IL-10
in response to the highest dose of OMVs (1010/mL) but at
109/mL Bt OMVs the proportion of mDC expressing IL-
10 was significantly (p < 0.01) reduced compared to HC
(Fig. 4c). Interestingly, when DC responses to Bt and Bt
OMVs were examined in UC patients with active disease,
the proportion of IL-10 expressing mDC was comparable
to that of healthy controls (Fig. 4d), suggesting intrinsic al-
terations in the immune system rather than inflammation
drives the loss of regulatory response to Bt OMV in UC.
Table 2 Clinical characteristics of St Mark’s Hospital blood donors and healthy volunteers
Characteristic Healthy control (HC) Ulcerative colitis (UC) Crohn’s disease (CD)
n 17 11 7
Male/female 7/10 4/7 2/5
Age at sampling 44.3 (17-86) 46 (26-65) 58.6 (23-80)
Inflammation categories
CRP (> 5) 3 1
ESR (> 20) 1 0
Faecal calprotectin (> 55) 2 1
Symptoms at sampling
Diverticular disease 1 0
Diversion colitis 0 1
Fistulating Crohn’s 0 1
IBD medications at sampling
None 9 5
Aminosalicylates 2 1
Azathioprine/6-mercaptopurine 0 0
Adalimumab 0 1
Non-IBD medications at sampling
Vitamins D/D3/ B12/B9 1 1
Loperamide 0 1
Alendronate 0 1
Metformin 1 0
Tamoxifen 1 0
Simvastatin 1 0
None 10 6
Demographic and clinical data analysed in Figs. 1, 2, 3, 4 and 5 and Supplementary Fig 1-4
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Specificity of DC cytokine response to commensal
bacteria
To determine if altered responses existed to bacteria
other than Bt in individuals with UC, circulating DC re-
sponses to a selection of 19 additional human intestinal
commensal bacteria were examined, including several
gram-negative species. As in previous experiments, dis-
ease activity was determined for UC patients using both
macroscopic histological findings from colonoscopy
(Table 1) and blood or faecal markers of inflammation
(Table 2). Inactive disease was defined as having macro-
scopically normal mucosa from rectum to TI from col-
onoscopy and/or not having inflammatory markers in
blood and faeces at time of sampling. For UC patients
with inactive disease, the proportion of mDC expressing
IL-10 in PBMC in response to each of the 19 bacteria
tested was comparable to HC (Fig. 5a).
We additionally examined circulating DC responses to a
gram-negative commensal of the human respiratory tract,
Prevotella nanceiensis (Pn), and its OMVs [57]. Pn, closely
related to Bt, exhibits weak inflammatory properties indi-
cating that it is tolerated by the respiratory immune sys-
tem [57, 58]. In response to non-viable (freeze-killed) Pn,
a proportion of mDC derived from PBMC of healthy
donors expressed both IL-6 (40-50 %) and IL-10 (10%)
(Fig. 5b). However, in contrast to the response to Bt
OMVs (Fig. 2b), the majority (≥ 80 %) of mDC did not ex-
press either IL-6 or IL-10 in response to Pn OMVs even
at the highest dose of 109 OMV/mL (Fig. 5b).
Further, in inactive UC patients, the proportion of
mDC expressing IL-6 or IL-10 in response to Pn OMVs
was comparable to HC with only IL-10 being reduced in
response to Pn (Fig. 5c). This suggests that the circulat-
ing DC IL-10 response elicited by Bt OMVs in HC may
be restricted to specific members of the microbiota, with
the reduced IL-10 response in inactive UC also poten-
tially being specific to Bt OMVs.
Discussion
Despite Bt being extensively used as a model organism
to study host immune-microbiota interactions [59], the
nature of the immune response to Bt in humans is
poorly characterised. Here, we present novel data show-
ing that the response of intestinal mucosal cells to Bt in-
volves a balance in the production of protective IL-6 and
regulatory IL-10 to which DC both locally and systemic-
ally contribute. Furthermore, this balanced response is
mediated by OMVs, nanosized vesicles produced by the
Fig. 3 Lack of IL-10 response from colonic DC to Bt OMVs in ulcerative colitis. Following 20 h culture of LP cells from five proximal and five distal
colon biopsies from UC patients with Bt OMVs 1010/mL or medium only, DC cytokine responses were examined by FACS. a Pooled data (n = 3)
showing proportions of mDC expressing IL-6 (top left) and IL-10 (top right) and representative FACS plots from one UC patient (bottom). b
Comparison of proportions of mDC expressing IL-6 (top) and IL-10 (bottom) in UC (n = 3) to HC (n = 6). Statistical significance was determined
using unpaired t tests; *p < 0.05
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bacteria which are known to cross the mucus layer of
the intestine to directly interact with immune cells be-
neath the boundary epithelium [60]. Furthermore, we
show that in individuals with CD and UC there is a loss
of regulatory IL-10 response to Bt OMVs by blood-
derived DC, while protective IL-6 responses are retained.
In UC, there is also a lack of colonic DC IL-10 response
to Bt OMVs and this accompanies a pronounced loss of
immunoregulatory CD103+ DC in the colonic LP. Im-
portantly, the altered circulating DC response to Bt
OMVs is only seen in UC and CD patients with inactive
disease, which suggests that underlying defects in the
immune system rather than inflammation drive these re-
sponses. IL-6 was significantly induced by Bt OMVs in
healthy individuals both in whole colonic biopsy cultures
as well as in blood DC. IL-6 is a pleiotropic cytokine
produced by innate immune cells like DC in response to
TLR stimulation. It has essential roles in driving B cell
differentiation and antibody production as well as main-
taining balanced CD4+ T helper responses by promoting
Th17/Tfh cells and inhibiting regulatory T cells [61].
However, aberrant IL-6 responses are implicated in the
pathogenesis of inflammatory diseases including Crohn’s
disease and ulcerative colitis and blockade of IL-6 is pro-
tective in murine colitis [62–64]. Therefore, it is not
surprising that we found an intact IL-6 response to Bt
OMVs in CD and UC comparable to HC specifically in
the periphery. However, in HC this was critically bal-
anced by a significant IL-10 response which is known to
directly inhibit IL-6-mediated responses [65–67]. In fact,
we have shown that both CD and UC are characterised
by heightened memory B cell and antibody responses to
the commensal microbiota and a lack of IL-10-mediated
suppression of IL-6 may directly contribute to this
skewed B cell response [36]. Further, in colonic LP of
UC patients, there was a clear lack of IL-6 and IL-10
production by DC to Bt OMVs suggesting a non-
responsive phenotype which may contribute to a loss of
colonic resident memory T cells in these patients [35,
36]. Thus, a deficient mucosal DC response to Bt OMVs,
possibly due to loss of key populations of CD103+ DC
and resident memory T cells, could lead to poorly regu-
lated systemic responses and pathology.
The marked DC IL-10 response to Bt OMV may be
specific as we did not see this response to OMVs gener-
ated by the closely related human lung commensal Pn
despite a comparable IL-10 response to the whole bac-
terium. This may be related to regional, tissue and mu-
cosa specific differences in addition to differences in
OMV cargo and specific antigens able to elicit the IL-10
Fig. 4 Loss of immunoregulatory IL-10 response by circulating DC to Bt OMVs in CD and UC. Whole PBMC were separated from blood of
individuals with inactive Crohn’s Disease (CD) or inactive or active ulcerative colitis (UC) and intracellular cytokine analysis of mDC was examined
by FACS. a Pooled data from inactive UC (n = 5) and CD (n = 5) patients show proportions of mDC expressing (a) IL-6 in response to Bt and Bt
OMVs and compared to HC. b Pooled data from inactive UC (n = 5) show proportions of mDC expressing IL-10 in response to Bt and Bt OMVs
and compared to HC. c Pooled data from inactive CD (n = 5) show proportions of mDC expressing IL-10 in response to Bt and Bt OMVs and
compared to HC. Statistical significance was determined by Brown-Forsythe and Welch ANOVA for unequal variance with Dunnett’s T3 multiple
comparisons test or two-way ANOVA with Holm Sidak’s multiple comparisons test; *p < 0.05, **p < 0.01, ***p < 0.001. d Pooled data from active
UC (n = 3) showing proportions of mDC expressing IL-6 (top) or IL-10 (bottom) and comparison to HC. Statistical significance was determined by
non-parametric Kruskal-Wallis ANOVA with Dunn’s multiple comparison test; *p < 0.05
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response by DC that are restricted to or are only access-
ible in Bt OMVs. An example of such species-specific
expression of immunomodulatory molecules is the cap-
sular polysaccharide A (PSA) antigen expressed by the
closely related commensal species Bacteroides fragilis
(Bf). The PSA antigen is expressed in Bf OMVs and
elicits IL-10 production from DC in a TLR-2-dependent
manner [23]. The immunomodulatory effect of Bt may
also not be restricted to immune cells and DC. In the
immortalised human colonic epithelial cell line Caco-2,
Bt stimulates nuclear export of the NFkB subunit RelA
in a mechanism involving PPARγ, which in turn
dampens inflammatory responses [9]. PPARγ-mediated
anti-inflammatory functions are well recognized, and ag-
onists are being explored in the treatment of UC [68]. Bt
has also been shown to contain a pyrin-like protein
(PLP) which in Caco-2 cells dampens the NFkB path-
ways [11]. Although neither PLP nor stimulation of
PPARγ has been linked to Bt OMVs directly, it is com-
patible with its potential immunomodulatory properties.
The NFkB pathways are directly involved in transcrip-
tional regulation of both IL-6 and IL-10 downstream of
TLR stimulation [62, 67] and Bt OMVs may act via these
pathways to control expression of these cytokines from
DC. Future work to characterise the contents of the
OMVs will be necessary to determine mechanisms of ac-
tion on DC in health or IBD.
The importance of regulatory IL-10 to the healthy re-
sponse of DC to Bt OMVs is congruent with observa-
tions in mice showing that Bt is colitogenic in dnKO
Fig. 5 Normal IL-10 response to other commensal bacterial species or OMVs in inactive UC. Whole PBMC from healthy individuals (n = 4) or
individuals with inactive UC (n = 3) were cultured for 20 h in the presence of 19 species of killed commensal bacteria. a Pooled data showing
proportions of mDC expressing IL-10 are shown as mean (+/− SEM). PBMC from healthy individuals (HC, n = 4-5) or inactive UC patients (n = 3)
were cultured for 20 h in the presence of Pn and Pn OMVs at varying concentrations. b The proportion of mDC expressing IL-6 or IL-10 from HC
is shown. c Proportions of mDC expressing IL-6 (top) and IL-10 (bottom) from inactive UC and compared to HC are shown. Statistical significance
was determined by ordinary one-way ANOVA with Dunnett’s multiple comparisons test or two-way ANOVA with Holm Sidak’s multiple
comparisons test; ****p < 0.0001
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mice lacking IL-10 and TGFβ-signalling pathways [10,
24]. Conversely, a strain of Bt different to that used in
our study was shown to protect otherwise susceptible
IL-10R-deficient mice or dextran sodium sulfate-treated
mice and rats from developing colitis [11]. These dis-
crepancies support the proposal that Bt protective func-
tions are, at least in mice, not limited to IL-10-related
pathways and may be dependent on environmental, bac-
terial strain- and host-specific factors [69]. Likewise in
humans, Bt OMVs could elicit immunomodulatory func-
tions via different mechanisms in addition to their role
in directing balanced DC responses that could change in
inflammatory settings such as in IBD. A recent study has
demonstrated a key role for IL-10R signalling in DC in
controlling aberrant Th1 responses both via inhibition of
IL-1β and IL-12 in paediatric IBD and in an individual
with IL10RA gene deficiency [70]. This fits with previous
reports that IL-10 is both produced by and acts via DC
to regulate intestinal inflammation [42]. In active UC,
there was no loss of IL-10 expression by circulating
mDC in response to Bt OMVs; however, it would have
been of interest to additionally determine if IL-10 was
able to inhibit downstream Th1 or Th17 type responses,
characteristic of IBD [71, 72]. Especially given the essen-
tial role, IL-6 plays in driving inflammatory T cell re-
sponses and antibody production, Bt OMV-mediated
induction of regulatory IL-10 may not be effective at
dampening these responses in the context of inflamma-
tion. Likewise, it is possible that the normal IL-10 re-
sponse in active UC is a result of DC or other cell types
such as T or B cells having lower IL-10R expression or
impaired pathway function leading to a positive feedback
loop to produce more IL-10.
Unlike whole bacteria, OMVs can cross from the
lumen of the intestine through the epithelial barrier and
access organs and tissues beyond the GI tract [17, 60].
Exploiting this property of OMV, Bt has been success-
fully engineered to generate OMVs containing both
therapeutic proteins and vaccine antigens for treating
mucosal inflammation and generating protective muco-
sal and systemic immunity [28, 29]. Thus, Bt OMVs
have considerable therapeutic potential. The fact that
circulating DC responses to Bt and their OMVs largely
reflect the local colonic DC response in health and in
disease is interesting on several levels. Firstly, if intestinal
disease activity can be assessed using a readout from the
blood, this avoids the necessity for taking additional bi-
opsies during colonoscopy. Secondly, the reduced IL-10
response to Bt OMVs in inactive UC was unique and
could not be recapitulated in response to another related
gram-negative commensal, Pn. Thus, Bt OMVs might be
of use in highlighting an immune signature specific to
UC that is detectable in blood samples. Finally, active in-
flammation appears to mask the underlying defects in
DC interplay with Bt OMVs, leading to a health-
associated circulating DC response. However, we did not
fully explore all possible cytokines or pathways elicited
by Bt OMVs and it is possible that in active IBD the sig-
nature may be distinct and different from health. For in-
stance, Bt has been shown to elicit IL-8 from paediatric
CD biopsies but not from healthy controls [73]. Add-
itionally, reduced IL10RA expression and reduced re-
sponsiveness occur in a subgroup of more severe
paediatric IBD patients and these are associated with en-
hanced IL-1β expression [70]. It will in future studies be
important to identify the specific factor or factors
present in Bt OMVs that trigger a healthy immune re-
sponse to realise their potential use as a novel therapy
for IBD.
Conclusions
Homeostatic and regulatory immune responses are gen-
erated to commensal bacteria both locally and systemic-
ally. For Bt, these responses involve a balance of host
protective IL-6 and regulatory IL-10 produced by DC.
Importantly, OMVs produced by Bt are instrumental in
eliciting this appropriate response both in the colonic
mucosa and in the blood. In patients with UC and CD,
there is a loss of regulatory IL-10 response by DC to Bt
OMVs which may contribute to the inflammatory milieu
of the intestine and systemically in these diseases.
Methods
Study design and sampling
The aim of this study was to characterise the human DC
response to Bt OMVs and determine whether it is al-
tered in IBD. Healthy donors (age 17-86) undergoing in-
vestigative colonoscopy and individuals diagnosed with
CD (age 21-80) and UC (age 24-70) were recruited from
outpatient clinics at St Marks Hospital, London North
West University Healthcare NHS Trust. Clinical charac-
teristics of patients and controls are in Tables 1 and 2.
Active disease for CD and UC was defined as having
macroscopic inflammation (rated from mild (1) to severe
(3); see Table 1) from colonoscopy findings and/or pres-
ence of blood inflammatory markers C-reactive protein
(CRP) > 5 and erythrocyte sedimentation rate (ESR) be-
tween 1 and 20 or faecal calprotectin > 55 (See Table 2).
Inactive disease was defined as no inflammation from
rectum to terminal ileum (TI) according to colonoscopy
findings and/or no more than one marker of inflamma-
tion in blood (CRP > 5 or ESR between 1 and 20) and
normal faecal calprotectin (< 55).
Patients were recruited over a fixed period determined
by ethical permission, and no data were excluded at the
end of the study. Additional healthy blood volunteers
were recruited from hospital staff and visitors. Ethics ap-
proval was obtained from the Health Research Authority
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UK and London Brent Research Ethics Committee.
Written informed consent was received from partici-
pants prior to inclusion in the study.
For whole biopsy culture experiments, healthy do-
nors were recruited from endoscopy clinics at Norfolk
and Norwich University Hospital following informed
consent (see Table 3 for demographics data). Ethics
approval was obtained from the University of East
Anglia Faculty of Medicine and Heath Sciences Ethics
Committee and Human Tissue Act Subcommittee ref
20152016-39HT and the Norfolk and Norwich Uni-
versity Hospital Research and Development Commit-
tee ref 20-01-16.
Preparation of bacteria stocks
Bacteroides thetaiotaomicron VPI-5482 (Bt) (DSMZ
2079) and Prevotella nanciensis (Pn) (DSMZ 19126)
(both from DSMZ-German Collection of Microorgan-
isms and Cell Cultures GmbH, Braunschweig,
Germany) were grown under anaerobic conditions at
37 °C in brain heart infusion (BHI) medium (Oxoid/
Thermo Fisher, Basingstoke, UK) supplemented with
0.5 mg/L haemin (Sigma-Aldrich, St Louis, MO, USA)
(BHI–haemin). Aliquots (1 mL) were centrifuged (13,
000 rpm for 10 min), supernatants removed and cell
pellets were killed by snap-freezing before storage at
−80 °C. Pellets were resuspended in phosphate-
buffered saline (PBS) for use. Other commensal bac-
teria were isolated from the caecum of healthy donors
with the exception of Collinsella aerofaciens, which
was from faeces [74–76]. Strains were grown anaer-
obically in Hungate tubes containing Wilkins-
Chalgren broth at 37 °C for 24 h. Cell pellets were
killed by snap-freezing at −80 °C and enumerated by
flow cytometry following SYBR Green staining.
Preparation of bacterial OMVs
The isolation of bacterial vesicles was done as previ-
ously described [25]. Briefly, Bt or Pn were grown
under anaerobic conditions at 37 °C in an anaerobic
cabinet. Bacterial starter cultures were grown over-
night in 20 mL BHI medium supplemented with
15 μM haemin (Sigma-Aldrich) (BHIH). An aliquot
(0.5 mL) of the starter culture was used to inoculate
500 mL BHI supplemented with 0.75 μM haemin.
Cells were harvested after 16 h at an approximate OD
(600 nm) of 4.0. The cells were centrifuged at 5500×g
for 45 min at 4 °C and the supernatants filtered
through polyethersulfone (PES) membranes (0.22 μm
pore size) (sartorius) to remove debris and cells. Su-
pernatants were concentrated by ultrafiltration (100
kDa molecular weight cutoff, Vivaspin 50R, sartorius),
the retentate was rinsed once with 500 mL of PBS
(pH 7.4) and concentrated to 0.5 mL.
Further purification was performed by fractionation of
the OMV suspension by size-exclusion chromatography
using a CL2-B sepharose (Sigma-Aldrich) column (120
cm × 1 cm) in PBS. The absorbance of the fractions was
measured at 280 nm and the first fractions displaying an
absorbance peak were pooled and concentrated down to
1 mL with a Vivaspin 20 centrifugal concentrator (100
kDa molecular weight cutoff, sartorius) and filtered
through a 0.22 μm PES membrane (sartorius). Concen-
tration of vesicles was determined using nanoparticle
tracking analysis as described previously [29]. Bt
OMVs were at 1011 vesicles/mL of PBS and Pn
OMVs were at 2 × 1010 vesicles/mL of PBS.
Transmission electron microscopy
Bt OMVs were observed using negative staining with
transmission electron microscopy (TEM) as previously
described [53]. Briefly, isolated Bt OMVs were adsorbed
to carbon–formvar-coated copper EM grids (Agar Scien-
tific) for 1 min before wicking off with filter paper and
negatively staining with 2% uranyl acetate solution
(BDH) in water for 1 min. Grids were air-dried before
analysis using a Tecnai G2 20 Twin TEM (FEI) at ×29,
000 magnification.
Polarised in vitro organ culture of colonic biopsies
Colonic biopsies were taken from the rectosigmoid
junction (around 18 cm from rectum) of macroscopic-
ally normal patients following informed consent. The
polarised in vitro culture (pIVOC) of colonic biopsies
used was adapted from a previous study [77]. Briefly,
five colonic biopsies were collected in IVOC medium
(Dulbecco’s Modified Eagle’s Medium (Sigma-Aldrich)
(45 %) and distilled water (45%) containing 0.47 g
NCTC-135 (Sigma-Aldrich), 0.11 g sodium bicarbon-
ate (Sigma-Aldrich) and 10% newborn calf serum
(NCS, Sigma-Aldrich). Each biopsy was orientated
with the mucosal side uppermost on a cellulose ni-
trate filter within a Snapwell support and mounted
within a well of a six-well plate containing 3 mL of
IVOC medium. Once mounted, 200 μL of IVOC
medium was added apically with or without 108-109
Bt OMVs/ml. The plate was incubated on a rotor (12
rpm) at 37 °C for 6 h, after which the biopsy was re-
moved intact from each support, flash-frozen in liquid
Table 3 Clinical characteristics of Norfolk and Norwich
University Hospital colonoscopy patients donating colonic
biopsies
Characteristic Healthy control (HC)
n 4
Male/female 3/1
Age at sampling 48.5 (39-66)
Demographic and clinical data analysed in Fig. 1b and Supplementary Fig 1a
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nitrogen and stored at −80 °C for later protein extrac-
tion and cytokine analysis.
Biopsy tissue lysate extraction
Biopsies were thawed on ice and a mixture of 122 μl
CellLytic MT (Sigma C3228), and 3 μl protease inhibitor
cocktail (Sigma P2714-1BTL) was added with 5 acid-
washed glass beads (3 mm diameter). Homogenisation
was performed using a MP Biomedical Fastprep-24 in-
strument (Fisher Scientific) at 4 m/s for 30 s. Samples
were centrifuged at 10,000 rpm at 4 °C for 2 min. The
tissue lysate was then transferred to a 1.5 ml pre-cooled
tube and centrifuged at 10,000 rpm for 10 min at 4 °C.
The supernatant was carefully removed and stored at
−80 °C until use for cytokine bead array (see below).
Isolation of colonic lamina propria cells
Five proximal and five distal colon biopsies (10 mg
tissue each) were obtained from macroscopically non-
lesional tissue sites at routine colonoscopy in all pa-
tients as previously described [55]. Biopsies were
washed in HBSS containing 1 mM DTT and 1 mM
EDTA in a shaking incubator at 37 °C for 30 min to
remove the epithelial layer. Supernatants were dis-
carded and wash was repeated for a second 30 min
with HBSS/DTT/EDTA. Following discard of superna-
tants, biopsies were further digested in RPMI medium
containing collagenase D (1 mg/mL) and Liberase TL
(0.1 mg/mL) for 1 h shaking at 37 °C to release the
lamina propria (LP) cells. LP cells were then filtered
through a 100 μM strainer, washed with PBS and cen-
trifuged at 600 g for 5 min before proceeding to either
culture or FACS staining.
Isolation of peripheral blood mononuclear cells
Blood obtained by venepuncture was diluted 1:1 (vol:
vol) in PBS and layered over Ficoll-Paque Plus
(Amersham Biosciences, Chalfont St. Giles, UK). After
centrifugation at 800 g for 30 min at 18 °C, PBMC
were collected at the interface. PBMC were resus-
pended in complete medium (Dutch modified RPMI
1640 (Sigma-Aldrich, Dorset, UK) containing 100 U/
mL penicillin/streptomycin, 2 mM L-glutamine, 50 μg/
mL gentamicin (Sigma-Aldrich) and 10% faetal calf
serum (TCS cell works, Buckingham, UK)) for culture
or in PBS for FACS analysis.
Bacterial stimulation of blood DC or LP cells
Per condition, 5 × 105 PBMC were plated in 96-well
U-bottom plates. PBMC were incubated with either
106/mL freeze-killed commensal bacteria or OMVs at
tenfold incremental concentrations from 1010 to 10
OMVs/mL at 37 °C, 5% CO2 for 20 h. LP cells were
isolated as described above and resuspended in
complete medium as described for PBMC. LP cells
(1-2 × 105 per condition) were plated in 96-well U-
bottomed plates. LP cells were incubated with either
107/mL freeze-killed Bt, 1010/mL of Bt OMVs or
complete medium only at 37 °C, 5% CO2 for 20 h. For
intracellular cytokine responses, 2 μM monensin (Bio-
legend) was added to wells during incubation.
Surface marker and intracellular cytokine profiling of DC
Following incubation, PBMC and LP cells were washed
with PBS and viability was determined by labelling cells
with LIVE/DEAD™ Fixable Near-IR Dead Cell Stain Kit
(Thermo Fisher Scientific) according to the manufac-
turer’s instructions. Cells were washed with FACS Buf-
fer (1x PBS containing 2% FCS, 1 mM ETDA and 0.02%
sodium azide) and then labelled with antibodies to
identify the dendritic cells (Table 4). Cells were fixed in
1% paraformaldehyde (PFA) if only surface markers
were examined.
For intracellular cytokine analysis, cells were fixed using
Leucoperm A buffer (Bio-Rad) and permeabilised using
Leucoperm B (Bio-Rad) and then labelled with antibodies
to interleukin (IL)-10 and IL-6 (Table 4). Finally, cells
were fixed again in 1% PFA and stored at 4 °C.
Flow cytometry
Single-cell suspensions were acquired on the BD FACS-
Canto II (BD Biosciences) or the BD LSR Fortessa (BD
Biosciences). Compensation was carried out on FACS
Diva software using Anti-Mouse Ig, κ/Negative Control
Compensation Particles Set (BD Biosciences) conjugated
to antibodies used in above labelling experiments. The
ArC™ Amine Reactive Compensation Bead Kit (Thermo
Fisher Scientific) was used for compensation of the
LIVE/DEAD™ Fixable Near-IR Dead Cell Stain according
to kit instructions. Data analysis was done using the
FlowJo_v.10 software.
Cytokine bead array
The LEGENDplex Human Inflammation Panel I (Biole-
gend, London, UK ) was used to simultaneously quantify
13 human cytokines/chemokines (IL-1β, IFN-α2, IFN-γ,
TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-
12p70, IL-17A, IL-18, IL-23, and IL-33) in biopsy tissue
lysates according to the manufacturer’s instructions and
analysed on a BD LSR Fortessa using the PE and APC
channels. Data were analysed using the LEGENDplex
data analysis software (Biolegend, London, UK). All cyto-
kines/chemokines were detectable apart from IFN-α2
which was below detection limits.
ELISA
PBMC were cultured with Bt or Bt OMVs as described
above and cell supernatants were taken at 20 h post-
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stimulation and stored at −80 °C. Amounts of cytokines
(IL-6 and IL-10) were measured using Human DuoSet
ELISA kits (R and D systems) according to the manufac-
turer’s instructions. Plates were read on the Tecan Infin-
ite F50 plate reader and data were analysed using the
MagellanTM software (Tecan Group Ltd, Mannedorf,
Switzerland).
Statistical analysis
Statistical analysis was carried out using the Graph-
Pad Prism software version 8. For in vitro experi-
ments, data were analysed using nonparametric
Mann-Whitney U tests (Fig. 1b and Supplementary
Figure 1a); unpaired t tests (Fig. 3); ordinary one-way
ANOVA with Dunnett’s multiple comparisons test
(Figs. 1d and 2b, d (IL-10), Fig. 5b and Supplemen-
tary Figure 2B), one-way ANOVA with Brown-Forsyth
and Welch corrections for unequal variance with
Dunnett’s T3 multiple comparisons test (Figs. 2c and
4a, b) or non-parametric Kruskal-Wallis ANOVA with
Dunn’s multiple comparisons test (Figs. 1e and 2d
(IL-6) and Fig. 4c) when making comparisons be-
tween experimental conditions within a single group;
or ordinary two-way ANOVA with Holm’s Sidak’s
multiple comparisons test (Figs. 4 and 5) for making
comparisons between groups for different experimen-
tal conditions. Colonic LP DC data from HC, CD and
UC patients (Supplementary Figure 3) were analysed
using non-parametric Kruskal-Wallis ANOVA with
Dunn’s multiple comparisons test; *p < 0.05.
Table 4 Antibodies used for FACS
Antigen Clone Isotype Fluorochrome Supplier
CD3 UCHT1 IgG1,k PE Cy5 BD Bioscience
CD14 61D3 IgG1,k PE Cy5 BioRad-Serotec
CD14 M5E2 IgG2a,k PerCP Cy5.5 BD Bioscience
CD14 MФP9 IgG2b,k PECF594 BD Horizon
CD16 3G8 IgG1,k PE Cy5 BD Bioscience
CD19 HIB19 IgG1,k PE Cy5 BD Bioscience
CD34 581 IgG1,k PE Cy5 BD Bioscience
CD64 10.1 IgG1,k PerCP Cy5.5 BD Bioscience
CD64 10.1 IgG1,k PE Cy5 Abcam
CD123 6H6 IgG1,k PE Cy7 eBioscience
HLA-DR G46-6 IgG2a APC BD Bioscience
HLA-DR L234 IgG2a BV421 Biolegend
HLA-DR L234 IgG2a BV570 Biolegend
CD11c B-Ly6 IgG1,k BV605 BD Bioscience
CD40 LOB7/6 IgG2a FITC AbD Serotec (Bio-Rad)
CD40 5C3 IgG1 BV711 BD Bioscience
CD45 H130 IgG1,k BUV395 BD Horizon
CD80 L307.4 IgG1,k FITC BD Bioscience
CD80 L307.4 IgG1,k PE BD Bioscience
CD86 BU63 IgG1 FITC AbD Serotec (Bio-Rad)
CD86 2331(FUN-1) IgG1,k AlexaFluor700 BD Pharmingen
CD103 (Integrin αE) Ber-Act8 IgG1,k BV421 Biolegend, BD Bioscience
IL-6 MQ2-13A5 IgG1,k Rat FITC Biolegend
IL-6 MQ2-13A5 IgG1,k Rat PE eBioscience
IL-10 JES-19F1 IgG1,k Rat PE Biolegend
IL-10 JES-19F1 IgG1,k Rat APC BD Bioscience/Biolegend
Integrin β7 FIB504 IgG2a, Rat PE Biolegend
Integrin β7 FIB504 IgG2a, Rat FITC Biolegend
Integrin β7 FIB504 IgG2a, Rat APC BD Bioscience
SIRPα (CD172a/b) SE5A5 IgG1,k PECy7 Biolegend
List of all antibodies used to identify and characterise human DC in circulation and in colon for Figs. 1, 2, 3, 4 and 5 and Supplementary Figs 1-4
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Additional file 1: Supplementary Figure 1. Bt OMVs induce diverse
cytokines from whole colon tissue and marked IL-10 response from co-
lonic LP mDC. Supplementary Figure 2. Plasmacytoid DC cytokine re-
sponse to Bt and Bt OMVs in healthy controls. Supplementary Figure
3. Loss of CD103+ DC in UC and CD colonic LP. Supplementary Figure
4. Bt OMVs do not induce IL-10-expressing mDC in colonic LP in ulcera-
tive colitis.
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